Belite Bio gives18 month data from 24 month study of Tinlarebant

Belite Bio presented 18-month data from its ongoing two-year, open-label Phase 2 clinical study of Tinlarebant in adolescent STGD1 patients as part of the poster presentation at the Association for Research in Vision and Ophthalmology ARVO Annual Meeting .Professor John Grigg, the study’s Principal Investigator and Head of Specialty Clinical Ophthalmology at the University of Sydney and Consultant Ophthalmologist at the Sydney Children’s Hospitals Network at Westmead and Sydney Eye Hospital was the presenter of this interim study data. "It is great to observe that the 18-month interim data showed a consistent safety profile in patients treated with Tinlarebant," said Dr. John Grigg. "Belite Bio’s current Phase 2 data also continued to demonstrate a promising trend toward slowing the disease progression in the study cohort." To date, twelve patients* have completed 18 months of treatment in the ongoing two-year Phase 2 study of Tinlarebant. Routine assessments were performed to evaluate safety and tolerability of Tinlarebant. Retinal imaging data have been collected for the evaluation of disease progression in all subjects. At Month 18, data from fundus autofluorescence imaging revealed that nearly 60% of subjects showed no incident atrophic retinal lesions. Mean visual acuity was stabilized in the study cohort throughout the 18-month treatment period. Nine of 12 patients experienced mild xanthopsia/chromatopsia and delayed dark adaptation and one of 12 patients experienced night vision impairment, all of which were mild in severity and well-tolerated.